Oral Gepants Have Disrupted Acute Migraine Management and Look Next to Transform Preventive Treatment, According to Both Primary Care Physicians and Specialists
New research from Spherix Global Insights finds the impressive uptake of AbbVie s Ubrelvy and Biohaven s Nurtec ODT appears to have already blunted reliance on the subcutaneous CGRP monoclonal antibodies, with growth of Amgen/Novartis Aimovig, Teva s Ajovy, and Eli Lilly s Emgality all moderating
News provided by
Share this article
Share this article
EXTON, Pa., May 6, 2021 /PRNewswire/ Both AbbVie s (formerly Allergan, an AbbVie company) Ubrelvy and Biohaven s Nurtec ODT are viewed by primary care physicians (PCPs) as strong entrants into the acute segment of the migraine market following their early 2020 launches. Interestingly, a new study from Spherix found similar physician-reported shares for both gepants [i.e., oral calcitonin gene-related peptide (CGRP) receptor antagonists], despite Ubrelvy s earlier launch.